...
首页> 外文期刊>Biomacromolecules >Poly(N-vinylformamide)-A Drag-Reducing Polymer for Biomedical Applications
【24h】

Poly(N-vinylformamide)-A Drag-Reducing Polymer for Biomedical Applications

机译:聚(N-乙烯基甲酰胺)-生物医学应用的减阻聚合物

获取原文
获取原文并翻译 | 示例

摘要

Water-soluble drag-reducing polymers (DRPs) were previously demonstrated to significantly increase blood flow,tissue perfusion,and tissue oxygenation when injected intravenously at nanomolar concentrations in various animal models.Turbulent flow drag-reducing ability was proven to be the most important factor defining the potential of polymers to favorably affect blood circulation.Several DRPs were applied in previous in vivo tests,but the search continues for suitable DRPs for biomedical applications.We demonstrated that poly(N-vinylformamide) (PNVF) with a molecular weight of 4.5 x 10~6 Da significantly reduced resistance to turbulent flow in a pipe and thus presents a DRP.We also found that the PNVF mechanical degradation is much slower than that of the most commonly used DRP,poly(ethylene oxide).PNVF is known to have low toxicity.Furthermore,our pilot in vivo study showed that PNVF had acceptable biocompatibility and hemodynamic effectiveness and thus could be considered as a DRP candidate for potential clinical use.
机译:先前已证明在各种动物模型中以纳摩尔浓度静脉内注射时,水溶性减阻聚合物(DRP)可以显着增加血流量,组织灌注和组织氧合。事实证明,湍流减阻能力是最重要的因素定义了聚合物有利地影响血液循环的潜力。先前的体内试验中使用了几种DRP,但仍在寻找适合生物医学应用的DRP。我们证明了分子量为4.5的聚(N-乙烯基甲酰胺)(PNVF) x 10〜6 Da显着降低了管道中的湍流阻力,因此形成了DRP。我们还发现PNVF的机械降解要比最常用的DRP聚环氧乙烷慢得多。此外,我们的体内实验研究表明PNVF具有可接受的生物相容性和血液动力学有效性,因此可以视为DRP c潜在的临床用途。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号